← FDA DRUG APPROVALS

FDA NDA · NDA217389

OHTUVAYRE

ensifentrine

Sponsor: MSD

APPLICATION
NDA217389
TYPE
NDA
ORIGINAL APPROVAL
2024-06-26
LATEST ACTION
2024-06-26
ROUTE
RESPIRATORY (INHALATION), INHALATION
DOSAGE FORM
SUSPENSION
MARKETING STATUS
Prescription

Products

OHTUVAYRE · ReferencePrescription
ENSIFENTRINE 3MG/2.5ML · SUSPENSION · INHALATION

Approval history

2024-06-26Type 1 - New Molecular Entity · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →